News
Community Update: LEMBAZ™ (adrabetadex) Is Approved
November 17, 2026
Beren Therapeutics Announces U.S. FDA Approval of LEMBAZ™ (adrabetadex), First & Only Medicine to Improve Survival in Infantile-Onset Niemann-Pick Disease, Type C
November 17, 2026
Beren Therapeutics Presents New Adrabetadex Data Showing Preservation of Neurological Function for More Than 10 Years in Children with Infantile-Onset NPC
October 15, 2026
Press Release
Community Update — Recognizing Niemann-Pick Awareness Month
October 1, 2026
Community Updates
Beren Therapeutics Launches ‘Test for NPC’ to Help Identify People with Niemann-Pick Disease, Type C Who Remain Undiagnosed
September 9, 2026
Press Release
Beren Therapeutics Expands Cyclodextrin Intellectual Property Estate with Eight New U.S. Issued Patents
August 6, 2026
Press Release
Community Update — Building Long-Term Support for Families
June 10, 2026
Community Updates
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
June 10, 2026
Press Release
Beren Therapeutics Announces Six Presentations at the 2026 Ara Parseghian Medical Research Fund (APMRF) Conference
May 29, 2026
Press Release
Beren Therapeutics Announces FDA Extension of Review Period for New Drug Application (NDA) for Adrabetadex for the Treatment of Infantile-Onset Niemann-Pick Disease, Type C
May 28, 2026
Press Release